Davis Polk and King & Wood Mallesons have represented Chinese medical device manufacturer Venus Medtech on its $331.17 million initial public offering on the Hong Kong Stock Exchange, with Latham & Watkins and Jingtian & Gongcheng advising the joint sponsors.
Venus Medtech focuses on R&D, manufacturing and commercialization of products designed for transcatheter implantation to replace dysfunctional heart valves mainly associated with aortic stenosis and pulmonic, mitral and tricuspid regurgitation.
According to the South China Morning Post, the offering had five cornerstone investors, including Asia-focused private-equity firm Hillhouse Capital and Singapore sovereign wealth fund GIC.
The Davis Polk team was led by partners Bonnie Y. Chan, Howard Zhang and Li He.
To contact the editorial team, please email ALBEditor@thomsonreuters.com.